Our recent SRMA looks at impact of #IBD therapies on bowel urgency, with all therapies improving BU significantly compared to placebo (some as soon as 48hrs after start of therapy) https://t.co/g83XeE4Q5h @vipuljairath @NarulaNeeraj @DrLexGI Chris Ma (@CalgaryIBD)

Join us for IBD Update on Tuesday, October 21 (7:00-8:00 PM ET) We will discuss the most clinically relevant IBD data from UEGW 2025 Register here: https://t.co/1GTzzjFaS9 Thank you to AbbVie, Celltrion, Eli Lilly, Johnson & Johnson, and Pfizer for sponsoring this event!

Ultra-Processed Grains and Risk of Inflammatory Bowel Disease: Results from the Prospective Urban Rural Epidemiology (PURE) Study Narula, et al. 📕 https://t.co/G7jvFfOp2j @NarulaNeeraj @ToYourHealth101 @marshllj @PaulMoayyedi @MLongMD @JasmohanBajaj

Our latest work in @IBDJournals reveals ☑️anti-TNFs heal UC in a proximal-to-distal pattern ☑️persistent proctitis at early follow-up may not indicate treatment failure if proximal healing is evident, ~60% went on to heal the rectum! https://t.co/fCQ9IHdelJ

@hasan_hamam @OUPAcademic https://t.co/wVi4CIH5LP @marshllj @PDulaiMD @ChrisMa_YYC @vipuljairath

Congrats to @hasan_hamam on his first author publication in #JCC @OUPAcademic which demonstrates UC patients who enter clinical trials using steroids have: ⬆️AEs compared to those not using concomitant steroids ⬆️AEs if not able to attain steroid-free CR (OR 4.5!)

https://t.co/rztRWQZyJH

🚨Out now @AmJGastro: Ultra-Processed Grains and Risk of Inflammatory Bowel Disease: Results from the Prospective Urban Rural Epidemiology (PURE) Study Ultra-processed grains (cereals, packaged breads, etc) 🔼 risk of UC and higher intake of UPF associated with 🔼 both CD/UC

Our latest work in @IBDJournals: Validation of the MM-SES-CD to predict endoscopic healing at one year. We also found it to be predictive of clinical and calprotectin remission! https://t.co/HABT7jvLls

Preliminary Results From a Multicenter Randomized Trial Using Fecal Microbiota Transplantation to Induce Remission in Patients With Mild-to-Moderate Crohn's Disease Kao, et al. 📕 https://t.co/oj2lVXlMnf @MLongMD @JasmohanBajaj @PaulMoayyedi @RPanaccione @NarulaNeeraj @madsen_ca

Just part of the McMaster IBD team on another busy day of clinic! @NarulaNeeraj @MacDeptMed @TheCDHF @getgutsycanada

Please join us for our post ECCO 2025 IBD Update to review the top presented abstracts. Expert commentary by @vipuljairath Join Here! https://t.co/TyGpYLus8x

@waqqasafif Sorry, was pointed out to me that the poster in my post is blurry! I've attached some of the figures here from the EASE PAIN study demonstrating decreased injection site events with biosimilar adalimumab AVT02 (Simlandi). Poster presented today at #CDDWCLM2025

Congrats to @VerduLab for receiving King Charles III Coronation Medal for her outstanding contributions to GI and celiac research! @machealthsci #cddwclm2025

Interim analysis results of the pan-Canadian EASE PAIN study, on the impact of switching patients (including Crohn’s disease/UC patients) to biosimilar adalimumab AVT02 (Simlandi), demonstrated a significant decrease in injection site pain. #CDDWCLM2025

The TRIUMPH study is now published in Crohns Colitis 360 @IBDJournals. Thank you to @CIRC_CCRM for their endorsement, the investigators, and the patients for their participation. Another step to understand use of JAK inhibitors in acute severe UC! https://t.co/3oX9oljJie

📢 New article on this #JCAGJeudi 📰 Acceptability, feasibility, and impact of the MyGut digital health platform in the monitoring and management of inflammatory bowel disease ✍️by Jamie Zhen, Maude Simoneau, Pooja Sharma, Pascale Germain and others 🔗 https://t.co/3F4MggP0B0

@marshllj @vipuljairath @PDulaiMD https://t.co/8ywnHDcMNd @OUPAcademic

EOSINOPHILS in IBD? Our work in #JCC suggests anti-IL-12/23 may be more effective in managing eosinophil-associated inflammation in IBD. Eosinophil reduction was identified as a marker of early response to ustekinumab in both UC/CD, but not adalimumab or vedolizumab. Link below